Aurinia Pharmaceuticals (AUPH) Net Income towards Common Stockholders (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.70% |
| Dec 31, 2025 | 567.96% |
| Sep 30, 2025 | 46.66% |
| Jun 30, 2025 | -7.86% |
| Mar 31, 2025 | 1,480.84% |
| Dec 31, 2024 | -89.68% |
| Sep 30, 2024 | 1,881.58% |
| Jun 30, 2024 | 106.72% |
| Mar 31, 2024 | 59.99% |
| Dec 31, 2023 | -99.80% |
| Sep 30, 2023 | -16.59% |
| Jun 30, 2023 | 55.99% |
| Mar 31, 2023 | -0.72% |
| Dec 31, 2022 | -189.44% |
| Sep 30, 2022 | 74.69% |
| Jun 30, 2022 | 5.62% |
| Mar 31, 2022 | -12.93% |
| Dec 31, 2021 | 33.69% |
| Sep 30, 2021 | -6.90% |
| Jun 30, 2021 | 6.69% |
| Mar 31, 2021 | -523.97% |
| Dec 31, 2020 | 98.17% |
| Sep 30, 2020 | -66.04% |
| Jun 30, 2020 | 8.22% |
| Mar 31, 2020 | 17.32% |
| Dec 31, 2019 | -145.13% |
| Sep 30, 2019 | -0.72% |
| Jun 30, 2019 | 6.59% |
| Mar 31, 2019 | -19.41% |
| Dec 31, 2018 | 27.80% |
| Sep 30, 2018 | -11.50% |
| Jun 30, 2018 | 17.72% |
| Mar 31, 2018 | -13.49% |
| Dec 31, 2017 | 15.39% |
| Sep 30, 2017 | 3.83% |
| Jun 30, 2017 | 5.41% |
| Mar 31, 2017 | -511.11% |
| Dec 31, 2016 | -17,118,947.62% |
| Sep 30, 2016 | -110.00% |
| Jun 30, 2016 | 23.08% |
| Mar 31, 2016 | 0.00% |
| Dec 31, 2015 | 18.75% |
| Sep 30, 2015 | -700.00% |